A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for freeBusiness Insider • 10/24/23
Pfizer's ‘casual' layoffs livestream is the next Better.com CEO gaffe—and workers are lividFast Company • 10/24/23
Pfizer hopes to avoid scaring investors when it reports 3Q results on HalloweenProactive Investors • 10/23/23
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billionMarket Watch • 10/23/23
Pfizer gets FDA green light for new shot that can streamline teenagers' vaccinationsMarket Watch • 10/20/23
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in AdolescentsBusiness Wire • 10/20/23
Biotech stocks are in a post-pandemic slump and recovery in 2024 is questionableMarket Watch • 10/20/23
Pfizer to more than double price of its COVID antiviral once drug moves to commercial marketMarket Watch • 10/19/23
Pfizer Reportedly Hikes Paxlovid Price To $1,390 — More Than Double What The Government PaidInvestors Business Daily • 10/19/23